{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:10:59Z","timestamp":1781151059728,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bbmt.2015.04.009","type":"journal-article","created":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T16:05:41Z","timestamp":1428681941000},"page":"1460-1470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen"],"prefix":"10.1016","volume":"21","author":[{"given":"Rebecca A.","family":"Marsh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marepalli B.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Gefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Bellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinda A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharat","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasiani C.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grimley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dandoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"El-Bietar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish R.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Leemhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack J.","family":"Bleesing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra H.","family":"Filipovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.04.009_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/jjco\/hyi211","article-title":"Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome\u2013single center experience","volume":"36","author":"Rzepecki","year":"2006","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.04.009_bib2","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","article-title":"Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation","volume":"116","author":"Marsh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib3","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","article-title":"An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis","volume":"19","author":"Marsh","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1705926","article-title":"Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen","volume":"41","author":"Hansen","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1704795","article-title":"A\u00a0novel reduced-intensity stem cell transplant regimen for nonmalignant disorders","volume":"35","author":"Shenoy","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bmt.2008.151","article-title":"Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome","volume":"42","author":"Bhatla","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib7","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1002\/pbc.25113","article-title":"Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease","volume":"61","author":"Oshrine","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2015.04.009_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1705923","article-title":"Reduced intensity conditioning and allogeneic stem cell transplantation in childhood malignant and nonmalignant diseases","volume":"41","author":"Satwani","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2012.12.005","article-title":"Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients","volume":"19","author":"Satwani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib11","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib12","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2015.04.009_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/146532401317070899","article-title":"Pharmacokinetics of CAMPATH-1H in BMT patients","volume":"3","author":"Rebello","year":"2001","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.04.009_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-02-0593","article-title":"Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration","volume":"104","author":"Hale","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","article-title":"Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response","volume":"64","author":"Mould","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2015.04.009_bib17","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","article-title":"Impact of in\u00a0vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution","volume":"116","author":"Chakraverty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib18","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","article-title":"In\u00a0vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation","volume":"96","author":"Kottaridis","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib20","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in\u00a0vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib21","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection","volume":"92","author":"Hale","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.04.009_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.bbmt.2006.05.006","article-title":"A\u00a0study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy","volume":"12","author":"Shore","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.bmt.1705263","article-title":"Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival","volume":"37","author":"Juliusson","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib24","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jcyt.2013.05.016","article-title":"Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery","volume":"15","author":"Gartner","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.04.009_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbmt.2013.11.005","article-title":"Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies","volume":"20","author":"Lane","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.04.009_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbmt.2013.11.021","article-title":"A\u00a0novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases","volume":"20","author":"Parikh","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115002530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115002530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:50:52Z","timestamp":1761058252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115002530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1083879115002530"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.009","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}